Medicinal Chemistry of Quinazolines as Anticancer Agents Targeting Tyrosine Kinases

Cancer is a large group of diseases that can affect any organ or body tissue due to the abnormal cellular growth with the unknown reasons. Many of the existing chemotherapeutic agents are highly toxic with a low level of selectivity. Additionally, they lead to development of therapeutic resistance. Hence, the development of targeted chemotherapeutic agents with low side effects and high selectivity is required for cancer treatment. Quinazoline is a vital scaffold well-known to be linked with several biological activities. The anticancer activity is one of the prominent biological activities of this scaffold. Several established anticancer quinazolines work by different mechanisms on the various molecular targets. The aim of this review is to present different features of medicinal chemistry as drug design, structure activity relationship, and mode of action of some targeted anticancer quinazoline derivatives. It gives comprehensive attention on the chemotherapeutic activity of quinazolines in the viewpoint of drug discovery and its development. This review provides panoramic view to the medicinal chemists for supporting their efforts to design and synthesize novel quinazolines as targeted chemotherapeutic agents.

[1]  M. Zayed.  Medicinal Chemistry of Quinazolines as Analgesic and Anti-Inflammatory Agents , 2022, ChemEngineering.

[2]  V. Gandin,et al.  New tricyclic systems as photosensitizers towards triple negative breast cancer cells , 2022, Archives of Pharmacal Research.

[3]  S. Bősze,et al.  Synthesis and SAR Analysis of Novel 4-Hydroxytamoxifen Analogues Based on Their Cytotoxic Activity and Electron-Donor Character , 2022, Molecules.

[4]  L. Cascione,et al.  Development of [1,2]oxazoloisoindoles tubulin polymerization inhibitors: Further chemical modifications and potential therapeutic effects against lymphomas. , 2022, European journal of medicinal chemistry.

[5]  M. El-Zahabi,et al.  Design, Synthesis, Molecular Modeling and Anti-Hyperglycemic Evaluation of Quinazoline-Sulfonylurea Hybrids as Peroxisome Proliferator-Activated Receptor Gamma (PPARγ) and Sulfonylurea Receptor (SUR) Agonists , 2022, International journal of molecular sciences.

[6]  A. Joseph,et al.  An appraisal of anticancer activity with structure–activity relationship of quinazoline and quinazolinone analogues through EGFR and VEGFR inhibition: A review , 2022, Drug development research.

[7]  Z. Hricovíniová,et al.  Antioxidant, Cytotoxic, Genotoxic, and DNA-Protective Potential of 2,3-Substituted Quinazolinones: Structure—Activity Relationship Study , 2021, International journal of molecular sciences.

[8]  M. Abdel-Kader,et al.  Synthesis of some quinazolinones inspired from the natural alkaloid L-norephedrine as EGFR inhibitors and radiosensitizers , 2020, Journal of enzyme inhibition and medicinal chemistry.

[9]  R. Bansal,et al.  Therapeutic progression of quinazolines as targeted chemotherapeutic agents. , 2020, European journal of medicinal chemistry.

[10]  Ginson George,et al.  Recent advances in the pharmacological diversification of quinazoline/quinazolinone hybrids , 2020, RSC advances.

[11]  J. Negi,et al.  Chemistry and activity of quinazoline moiety: A systematic review study , 2020 .

[12]  L. A. Picos-Corrales,et al.  Synthesis, biological evaluation and molecular docking of 3-substituted quinazoline-2,4(1H, 3H)-diones , 2020, Journal of Chemical Sciences.

[13]  A. Simeonov,et al.  Design, Synthesis and Biological Evaluation of Quinazolin-4-one Based Hydroxamic Acids as Dual PI3K/HDAC Inhibitors. , 2020, Journal of medicinal chemistry.

[14]  Daoping Wang,et al.  Design, synthesis, biological evaluation of 6-(2-amino-1H-benzo[d]imidazole-6-yl)quinazolin-4(3H)-one derivatives as novel anticancer agents with Aurora kinase inhibition. , 2020, European journal of medicinal chemistry.

[15]  A. Sivaramakrishna,et al.  Remarkably flexible quinazolinones—synthesis and biological applications , 2020 .

[16]  M. Lahtinen,et al.  Synthesis, characterization, crystal structures and biological screening of 4-amino quinazoline sulfonamide derivatives , 2019, Journal of Molecular Structure.

[17]  Debasis Das,et al.  Recent advancements of 4-aminoquinazoline derivatives as kinase inhibitors and their applications in medicinal chemistry. , 2019, European journal of medicinal chemistry.

[18]  Chae S. Yi,et al.  Synthesis of Quinazoline and Quinazolinone Derivatives via Ligand-Promoted Ruthenium-Catalyzed Dehydrogenative and Deaminative Coupling Reaction of 2-Aminophenyl Ketones and 2-Aminobenzamides with Amines. , 2019, Organic letters.

[19]  Marawan Ahmed,et al.  Design, synthesis, biological evaluation and dynamics simulation of indazole derivatives with antiangiogenic and antiproliferative anticancer activity. , 2019, Bioorganic chemistry.

[20]  S. Ibrahim,et al.  Design, synthesis, antimicrobial and anti-biofilm evaluation, and molecular docking of new substituted fluoroquinazolinones. , 2019, Medicinal chemistry (Shariqah (United Arab Emirates)).

[21]  R. Jain,et al.  Design, synthesis and evaluation of novel 2, 3-disubstituted-4-(3H) quinazolinone derivatives , 2018, Asian Journal of Pharmacy and Pharmacology.

[22]  Quentin Liu,et al.  Structure-based drug design: Synthesis and biological evaluation of quinazolin-4-amine derivatives as selective Aurora A kinase inhibitors. , 2018, European journal of medicinal chemistry.

[23]  S. Ibrahim,et al.  Quinazolinone-Amino Acid Hybrids as Dual Inhibitors of EGFR Kinase and Tubulin Polymerization , 2018, Molecules.

[24]  Hany E. A. Ahmed,et al.  Design, Synthesis, Cytotoxic Evaluation and Molecular Docking of New Fluoroquinazolinones as Potent Anticancer Agents with Dual EGFR Kinase and Tubulin Polymerization Inhibitory Effects , 2018, International journal of molecular sciences.

[25]  P. Trimboli,et al.  Efficacy of Vandetanib in Treating Locally Advanced or Metastatic Medullary Thyroid Carcinoma According to RECIST Criteria: A Systematic Review and Meta-Analysis , 2018, Front. Endocrinol..

[26]  M. J. Akhtar,et al.  Current perspectives on quinazolines with potent biological activities: A review , 2018 .

[27]  Hongjian Xu,et al.  6,7-Dimorpholinoalkoxy quinazoline derivatives as potent EGFR inhibitors with enhanced antiproliferative activities against tumor cells. , 2018, European journal of medicinal chemistry.

[28]  Yifan Feng,et al.  Novel 6-aryl substituted 4-pyrrolidineaminoquinazoline derivatives as potent phosphoinositide 3-kinase delta (PI3Kδ) inhibitors. , 2018, Bioorganic & medicinal chemistry.

[29]  Huan Sun,et al.  Novel quinazoline derivatives bearing various 6-benzamide moieties as highly selective and potent EGFR inhibitors. , 2018, Bioorganic & medicinal chemistry.

[30]  A. Hameed,et al.  Quinazoline and quinazolinone as important medicinal scaffolds: a comparative patent review (2011–2016) , 2018, Expert opinion on therapeutic patents.

[31]  F. Fu,et al.  Design and Discovery of Quinazoline- and Thiourea-Containing Sorafenib Analogs as EGFR and VEGFR-2 Dual TK Inhibitors , 2017, Molecules.

[32]  H. Bhatt,et al.  A comprehensive review on Aurora kinase: Small molecule inhibitors and clinical trial studies. , 2017, European journal of medicinal chemistry.

[33]  T. Lu,et al.  Design, synthesis and biological evaluation of 2,3-dihydroimidazo[1,2- c ]quinazoline derivatives as novel phosphatidylinositol 3-kinase and histone deacetylase dual inhibitors , 2017 .

[34]  G. Lenz,et al.  Phosphatidylinositol 3-Kinase Inhibition by Copanlisib in Relapsed or Refractory Indolent Lymphoma. , 2017, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[35]  Huabei Zhang,et al.  Development of a series of novel 4-anlinoquinazoline derivatives possessing quinazoline skeleton: Design, synthesis, EGFR kinase inhibitory efficacy, and evaluation of anticancer activities in vitro. , 2017, European journal of medicinal chemistry.

[36]  Li Chen,et al.  Novel 4-arylaminoquinazoline derivatives with (E)-propen-1-yl moiety as potent EGFR inhibitors with enhanced antiproliferative activities against tumor cells. , 2017, European journal of medicinal chemistry.

[37]  Shagufta,et al.  An insight into the therapeutic potential of quinazoline derivatives as anticancer agents. , 2017, MedChemComm.

[38]  San-qi Zhang,et al.  Design and synthesis of novel 6-aryl substituted 4-anilinequinazoline derivatives as potential PI3Kδ inhibitors. , 2017, Bioorganic & medicinal chemistry letters.

[39]  Chenze Qi,et al.  A novel quinazoline-based analog induces G2/M cell cycle arrest and apoptosis in human A549 lung cancer cells via a ROS-dependent mechanism. , 2017, Biochemical and biophysical research communications.

[40]  Li Chen,et al.  Synthesis and in vitro biological evaluation of novel quinazoline derivatives. , 2017, Bioorganic & medicinal chemistry letters.

[41]  Jyoti Monga,et al.  Design, synthesis and cytotoxic evaluation of novel imidazolone fused quinazolinone derivatives , 2017 .

[42]  Hany E. A. Ahmed,et al.  Synthesis, Modelling, and Anticonvulsant Studies of New Quinazolines Showing Three Highly Active Compounds with Low Toxicity and High Affinity to the GABA-A Receptor , 2017, Molecules.

[43]  Li‐Ping Sun,et al.  Design and discovery of 4-anilinoquinazoline-urea derivatives as dual TK inhibitors of EGFR and VEGFR-2. , 2017, European journal of medicinal chemistry.

[44]  San-qi Zhang,et al.  Discovery of 6-benzamide Containing 4-phenylquinazoline Derivatives as Novel PI3Kδ Inhibitors , 2016 .

[45]  Yung Chang Hsu,et al.  Discovery of BPR1K871, a quinazoline based, multi-kinase inhibitor for the treatment of AML and solid tumors: Rational design, synthesis, in vitro and in vivo evaluation , 2016, Oncotarget.

[46]  Y. Yao,et al.  One-pot synthesis and antifungal activity against plant pathogens of quinazolinone derivatives containing an amide moiety. , 2016, Bioorganic & medicinal chemistry letters.

[47]  P. Liu,et al.  Novel morpholin-3-one fused quinazoline derivatives as EGFR tyrosine kinase inhibitors. , 2016, Bioorganic & medicinal chemistry letters.

[48]  Xiaodong Ma,et al.  Novel 4-anilinoquinazoline derivatives featuring an 1-adamantyl moiety as potent EGFR inhibitors with enhanced activity against NSCLC cell lines. , 2016, European journal of medicinal chemistry.

[49]  Li‐Ping Sun,et al.  Design and discovery of 4-anilinoquinazoline-acylamino derivatives as EGFR and VEGFR-2 dual TK inhibitors. , 2016, European journal of medicinal chemistry.

[50]  Sonia Sharma,et al.  A novel quinazolinone chalcone derivative induces mitochondrial dependent apoptosis and inhibits PI3K/Akt/mTOR signaling pathway in human colon cancer HCT-116 cells. , 2016, Food and chemical toxicology : an international journal published for the British Industrial Biological Research Association.

[51]  Dong Chen,et al.  Structure-activity study of quinazoline derivatives leading to the discovery of potent EGFR-T790M inhibitors. , 2015, European journal of medicinal chemistry.

[52]  Yanmei Zhang,et al.  Synthesis and Evaluation of Novel Erlotinib-NSAID Conjugates as More Comprehensive Anticancer Agents. , 2015, ACS medicinal chemistry letters.

[53]  Hany E. A. Ahmed,et al.  Synthesis and screening of some new fluorinated quinazolinone–sulphonamide hybrids as anticancer agents , 2015 .

[54]  L. Gelbert,et al.  Cyclin dependent kinase (CDK) inhibitors as anticancer drugs. , 2015, Bioorganic & Medicinal Chemistry Letters.

[55]  M. Clausen,et al.  FDA-approved small-molecule kinase inhibitors. , 2015, Trends in pharmacological sciences.

[56]  Yongzhou Hu,et al.  Identification of novel 4-anilinoquinazoline derivatives as potent EGFR inhibitors both under normoxia and hypoxia. , 2014, Bioorganic & medicinal chemistry.

[57]  M. Asif.  Chemical Characteristics, Synthetic Methods, and Biological Potential of Quinazoline and Quinazolinone Derivatives , 2014, International journal of medicinal chemistry.

[58]  Jun-qing Chen,et al.  Discovery of 4-aminoquinazoline--urea derivatives as Aurora kinase inhibitors with antiproliferative activity. , 2014, Bioorganic & medicinal chemistry.

[59]  A. Markham.  Idelalisib: First Global Approval , 2014, Drugs.

[60]  M. Zayed.  New fluorinated quinazolinone derivatives as anticonvulsant agents , 2014 .

[61]  P. Depreux,et al.  Inhibition of tumor cell growth and angiogenesis by 7-aminoalkoxy-4-aryloxy-quinazoline ureas, a novel series of multi-tyrosine kinase inhibitors. , 2014, European journal of medicinal chemistry.

[62]  Memy H Hassan,et al.  Synthesis and biological evaluation studies of novel quinazolinone derivatives as antibacterial and anti-inflammatory agents. , 2014, Saudi pharmaceutical journal : SPJ : the official publication of the Saudi Pharmaceutical Society.

[63]  Juan Wang,et al.  Discovery of 2-methoxy-3-phenylsulfonamino-5-(quinazolin-6-yl or quinolin-6-yl)benzamides as novel PI3K inhibitors and anticancer agents by bioisostere. , 2014, European journal of medicinal chemistry.

[64]  F. Totzke,et al.  Novel 2-chloro-4-anilino-quinazoline derivatives as EGFR and VEGFR-2 dual inhibitors. , 2014, European journal of medicinal chemistry.

[65]  Hualiang Jiang,et al.  Design, synthesis and biological evaluation of novel 4-anilinoquinazolines with C-6 urea-linked side chains as inhibitors of the epidermal growth factor receptor. , 2013, Bioorganic & medicinal chemistry.

[66]  Weili Zhao,et al.  Four-membered heterocycles-containing 4-anilino-quinazoline derivatives as epidermal growth factor receptor (EGFR) kinase inhibitors. , 2013, Bioorganic & medicinal chemistry letters.

[67]  T. Mikkelsen,et al.  Phase III randomized trial comparing the efficacy of cediranib as monotherapy, and in combination with lomustine, versus lomustine alone in patients with recurrent glioblastoma. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[68]  Paola Brun,et al.  Quinazoline-based multi-tyrosine kinase inhibitors: synthesis, modeling, antitumor and antiangiogenic properties. , 2013, European journal of medicinal chemistry.

[69]  Jun Lin,et al.  Novel 5-anilinoquinazoline-8-nitro derivatives as inhibitors of VEGFR-2 tyrosine kinase: synthesis, biological evaluation and molecular docking. , 2013, Organic & biomolecular chemistry.

[70]  F. Gao,et al.  Quinazoline derivatives: synthesis and bioactivities , 2013, Chemistry Central Journal.

[71]  Jun-qing Chen,et al.  Design and synthesis of novel 4-benzothiazole amino quinazolines Dasatinib derivatives as potential anti-tumor agents. , 2013, European journal of medicinal chemistry.

[72]  Hany E. A. Ahmed,et al.  Design, synthesis, and biological evaluation studies of novel quinazolinone derivatives as anticonvulsant agents , 2013, Medicinal Chemistry Research.

[73]  Memy H. Hassan,et al.  Design, Synthesis and Biological Evaluation Studies of Novel Quinazoline Derivatives as Cytotoxic Agents , 2013, Drug Research.

[74]  Fuyi Wang,et al.  Synthesis, characterization, screening and docking analysis of 4-anilinoquinazoline derivatives as tyrosine kinase inhibitors. , 2013, European journal of medicinal chemistry.

[75]  K. Abouzid,et al.  Design, synthesis and in vitro anti-proliferative activity of 4,6-quinazolinediamines as potent EGFR-TK inhibitors. , 2013, European journal of medicinal chemistry.

[76]  M. Radi,et al.  Vascular endothelial growth factor (VEGF) receptors: drugs and new inhibitors. , 2012, Journal of medicinal chemistry.

[77]  Dongdong Li,et al.  Discovery of 6-substituted 4-anilinoquinazolines with dioxygenated rings as novel EGFR tyrosine kinase inhibitors. , 2012, Bioorganic & medicinal chemistry letters.

[78]  P. Depreux,et al.  Synthesis and structure-activity relationships of (aryloxy)quinazoline ureas as novel, potent, and selective vascular endothelial growth factor receptor-2 inhibitors. , 2012, Journal of medicinal chemistry.

[79]  Dongdong Li,et al.  Design and synthesis of 4,6-substituted-(diaphenylamino)quinazolines as potent EGFR inhibitors with antitumor activity. , 2012, Bioorganic & medicinal chemistry.

[80]  Yankun Hou,et al.  The combination of 4-anilinoquinazoline and cinnamic acid: a novel mode of binding to the epidermal growth factor receptor tyrosine kinase. , 2011, Bioorganic & medicinal chemistry.

[81]  P. Depreux,et al.  Impact of aryloxy-linked quinazolines: a novel series of selective VEGFR-2 receptor tyrosine kinase inhibitors. , 2011, Bioorganic & medicinal chemistry letters.

[82]  B. Rini,et al.  A phase II study of tandutinib (MLN518), a selective inhibitor of type III tyrosine receptor kinases, in patients with metastatic renal cell carcinoma , 2012, Investigational New Drugs.

[83]  Yong Ai,et al.  Molecular Modeling Studies of 4,5-Dihydro-1H-pyrazolo[4,3-h] quinazoline Derivatives as Potent CDK2/Cyclin A Inhibitors Using 3D-QSAR and Docking , 2010, International journal of molecular sciences.

[84]  Liang Xu,et al.  Design and synthesis of novel Gefitinib analogues with improved anti-tumor activity. , 2010, Bioorganic & medicinal chemistry.

[85]  N. Russell,et al.  The FLT3 Internal Tandem Duplication Mutation Is a Secondary Target of the Aurora B Kinase Inhibitor AZD1152-HQPA in Acute Myelogenous Leukemia Cells , 2010, Molecular Cancer Therapeutics.

[86]  M. Conconi,et al.  Exploring epidermal growth factor receptor (EGFR) inhibitor features: the role of fused dioxygenated rings on the quinazoline scaffold. , 2010, Journal of medicinal chemistry.

[87]  K. Abouzid,et al.  Design, synthesis and in vitro antitumor activity of 4-aminoquinoline and 4-aminoquinazoline derivatives targeting EGFR tyrosine kinase. , 2008, Bioorganic & medicinal chemistry.

[88]  Johanna Andrae,et al.  Role of platelet-derived growth factors in physiology and medicine. , 2008, Genes & development.

[89]  N. Keen,et al.  Synthesis and SAR of 1-acetanilide-4-aminopyrazole-substituted quinazolines: selective inhibitors of Aurora B kinase with potent anti-tumor activity. , 2008, Bioorganic & Medicinal Chemistry Letters.

[90]  James M. Roberts,et al.  CDK Inhibitors : Cell Cycle Regulators and Beyond , 2008 .

[91]  Bernd Giese,et al.  Targeting phosphoinositide 3-kinase: moving towards therapy. , 2008, Biochimica et biophysica acta.

[92]  Ying-Ta Wu,et al.  Synthesis and biological evaluation of substituted 6-alkynyl-4-anilinoquinazoline derivatives as potent EGFR inhibitors. , 2007, Bioorganic & medicinal chemistry letters.

[93]  N. Keen,et al.  Discovery, synthesis, and in vivo activity of a new class of pyrazoloquinazolines as selective inhibitors of aurora B kinase. , 2007, Journal of medicinal chemistry.

[94]  J. Breed,et al.  SAR and inhibitor complex structure determination of a novel class of potent and specific Aurora kinase inhibitors. , 2006, Bioorganic & medicinal chemistry letters.

[95]  Rajesh Odedra,et al.  Discovery of novel and potent thiazoloquinazolines as selective Aurora A and B kinase inhibitors. , 2006, Journal of medicinal chemistry.

[96]  M. Barbacid,et al.  Mammalian cyclin-dependent kinases. , 2005, Trends in biochemical sciences.

[97]  P. Guiry,et al.  Synthesis of Quinazolinones and Quinazolines , 2005 .

[98]  D. W. Fry,et al.  2-Aminoquinazoline inhibitors of cyclin-dependent kinases. , 2005, Bioorganic & medicinal chemistry letters.

[99]  P. D. Andrews,et al.  Aurora kinases: shining lights on the therapeutic horizon? , 2005, Oncogene.

[100]  J. Ruderman,et al.  Aurora kinase inhibitor ZM447439 blocks chromosome-induced spindle assembly, the completion of chromosome condensation, and the establishment of the spindle integrity checkpoint in Xenopus egg extracts. , 2005, Molecular biology of the cell.

[101]  Peter Vaupel,et al.  The role of hypoxia-induced factors in tumor progression. , 2004, The oncologist.

[102]  J. Mestan,et al.  Advances in the structural biology, design and clinical development of VEGF-R kinase inhibitors for the treatment of angiogenesis. , 2004, Biochimica et biophysica acta.

[103]  D. Zaller,et al.  Structural basis for p38α MAP kinase quinazolinone and pyridol-pyrimidine inhibitor specificity , 2003, Nature Structural Biology.

[104]  T. Hunter,et al.  Oncogenic kinase signalling , 2001, Nature.

[105]  G L Trainor,et al.  Quinazolines as cyclin dependent kinase inhibitors. , 2001, Bioorganic & medicinal chemistry letters.

[106]  L. Kuyper,et al.  Binding mode of the 4-anilinoquinazoline class of protein kinase inhibitor: X-ray crystallographic studies of 4-anilinoquinazolines bound to cyclin-dependent kinase 2 and p38 kinase. , 2000, Journal of medicinal chemistry.

[107]  John F. Meyer,et al.  THE NIEMENTOWSKI REACTION. THE USE OF METHYL ANTHRANILATE OR ISATOIC ANHYDRIDE WITH SUBSTITUTED AMIDES OR AMIDINES IN THE FORMATION OF 3-SUBSTITUTED-4-KETO-3,4-DIHYDROQUINAZOLINES. THE COURSE OF THE REACTION , 1943 .